Fusion protein having enhanced in vivo erythropoietin activity

Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit, for increasing an in vivo half-life activity of EPO....

Full description

Saved in:
Bibliographic Details
Main Authors Lee, Dong-eok, Oh, Myung-suk, Kim, Ki-wan, Chung, Bo-sup, Park, Ji-sook
Format Patent
LanguageEnglish
Published 15.08.2006
Online AccessGet full text

Cover

More Information
Summary:Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.